Anbio Biotechnology NNNN reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in ...
The United States market has shown impressive growth, rising 3.0% over the last week and 26% over the past year, with earnings projected to increase by 16% annually. In this robust environment, ...
FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, ...
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 08, ...
FRANKFURT, Germany, Jan. 9, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in diagnostics innovation, announces the launch of its Dry Chemiluminescence Immunoassay (CLIA) Solution ...
Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles ...
FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results